Crossmark

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Crossref DOI link: https://doi.org/10.1038/s41392-024-01857-6

Published Online: 2024-06-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sha, Huizi

Tong, Fan

Ni, Jiayao

Sun, Yi https://orcid.org/0000-0002-3818-1260
Zhu, Yahui

Qi, Liang

Li, Xiaoqin

Li, Wei

Yang, Yan

Gu, Qing

Zhang, Xing

Wang, Xiaoxuan

Zhu, Chan

Chen, Dongsheng

Liu, Baorui

Du, Juan
License Information

Text and Data Mining valid from 2024-06-07

Version of Record valid from 2024-06-07
More Information

Article History

Received: 20 December 2023

Revised: 29 April 2024

Accepted: 9 May 2024

First Online: 7 June 2024

Competing interests

: X.Z., C.Z., X.W., and D.C. were employed by Jiangsu Simcere Diagnostics Co., Ltd. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below